After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human immune system is still “mind-blowing” for molecular biologist Joshua Modell of ...

Fighting off pathogens is a tour de force that must happen with speed and precision. A team of researchers at CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, and at ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...

Martin Kampmann’s work, supported by the National Institutes of Science (NIH), maps cellular “decision points” that determine ...

St. Jude researchers advance CASTs, enhancing precision and activity for next-generation genome-editing therapies.

CRISPR’s gene-editing technology inspires Louis Gale to blur the lines between science and philosophy in his latest novel. “The idea of human evolution has intrigued scientists from the very beginning ...

Crispr Therapeutics AG remains undervalued despite recent stock volatility and slow Casgevy commercial uptake, with long-term potential intact. Casgevy's strong clinical data and broad approvals are ...